The authors received no financial support for this research and publication and have no conflict of interest.
Version of Record online: 30 MAY 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 106, Issue 8, pages 959–965, 15 December 2012
How to Cite
Huang, J.-F., Wu, S.-M., Wu, T.-H., Lee, C.-F., Wu, T.-J., Yu, M.-C., Chan, K.-M. and Lee, W.-C. (2012), Liver resection for complicated hepatocellular carcinoma: Challenges but opportunity for long-term survivals. J. Surg. Oncol., 106: 959–965. doi: 10.1002/jso.23172
Jen-Fu Huang and Sheng-Mao Wu contributed equally to this work.
- Issue online: 14 NOV 2012
- Version of Record online: 30 MAY 2012
- Manuscript Accepted: 4 MAY 2012
- Manuscript Received: 11 NOV 2011
- liver resection;
- hepatocellular carcinoma;
Hepatocellular carcinoma (HCC) is often diagnosed late because of the lack of pathognomonic symptoms. This study evaluated outcomes following liver resection (LR) for patients with HCC presenting with large tumor size (over 10 cm), adjacent organ invasion, or ruptured tumor, which we termed as complicated HCC (cHCC).
Materials and Methods
We retrospectively reviewed 660 HCC patients who underwent LR between January 2001 and July 2005. The patients were grouped into cHCC and non-cHCC according to the defined criteria. The clinicopathological features were analyzed and compared between the two groups.
Patients in the cHCC group required longer operative times and resulted in greater intraoperative blood loss and more severe surgical complications. The cHCC group had a higher incidence of HCC recurrence after LR, and the HCC recurrence had a tendency to be associated with extrahepatic metastasis. The 5-year RFS (P < 0.0001) and OS (P < 0.0001) of cHCC and non-cHCC patients were 18.5% and 28.9% versus 37.5% and 57.6%, respectively.
LR for cHCC can be a great challenge for liver surgeons. However, with comparable operative mortality rates and acceptable survival times, surgical resection should always be considered performing in patients with cHCC, if clinically feasible. J. Surg. Oncol. 2012; 106: 959–965. © 2012 Wiley Periodicals, Inc.